Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease. The pharma giant halted the phase 1 trial of QEQ278 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results